Investigational drug · Phase 2
CBP-0276
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriasis, Arthritic Psoriasis, Hip or Knee Replacement.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "CBP-0276"
First trial start
2025
Oct 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CBP-0276", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
- Arthritic Psoriasis
- Hip or Knee Replacement
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "CBP-0276" as an intervention, largest first.
- Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)Pivotal-lookingNot yet recruiting
Clarent Biopharma, Inc.Industry
NCT07706530 · 240 participants (planned) · Start Jul 2026 · Primary completion Feb 2027
Drug: CBP-0276 capsules 100mg; Placebo · For: Arthritic Psoriasis
Sites: Mexico City, Mexico
- Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in SubjectsPivotal-lookingRecruiting
Clarent Biopharma, Inc.Industry
NCT07204639 · 100 participants (planned) · Start Oct 1, 2025 · Primary completion Jul 31, 2026
Drug: CBP-0276 200mg BID; Placebo for CBP-0276 · For: Psoriasis
Sites: Mexico City, Mexico
Clarent Biopharma, Inc.Industry
NCT07687966 · 80 participants (planned) · Start May 8, 2026 · Primary completion Jun 30, 2026
Drug: CBP-0276; Placebo for CBP-0276 · For: Hip or Knee Replacement
Sites: Mexico City, Mexico
- Trial on Single/Multiple Ascending Doses for Safety, PK and PD for CBP-0276 in Healthy SubjectsCompleted
Clarent Biopharma, Inc.Industry
NCT07708831 · 64 participants · Start Sep 4, 2025 · Primary completion Feb 16, 2026
Drug: CBP-0276 Acetate; Placebo for CBP-0276 Acetate · For: Healthy Volunteers
Sites: Guadalajara, Mexico; Mexico City, Mexico
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Psoriasis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- CMAB015Phase 31 trial
Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis
- HPP737Phase 31 trial
Newsoara Biopharma Co., Ltd. · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.